We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Boston Scientific to Acquire Bayer’s Interventional Division

By HospiMedica International staff writers
Posted on 25 May 2014
In a move to significantly expand its portfolio of solutions for peripheral interventions, Boston Scientific (Natick, MA, USA) has entered into a definitive agreement to acquire the Interventional Division of Bayer (Leverkusen, Germany) for USD 415 million in cash.

The acquisition is expected to strengthen Boston Scientific’s peripheral interventions business and support the company’s strategy to expand the portfolio of peripheral vascular disease solutions, especially in the peripheral atherectomy and thrombectomy categories. More...
Upon completion of the transaction, Bayer Interventional will become part of the existing Boston Scientific peripheral interventions business. Closing of the transaction is subject to customary conditions, including relevant antitrust clearance, and is expected to occur in the second half of 2014.

The transaction includes the AngioJet Thrombectomy System, which breaks apart and removes blood clots from within blood vessels, and the Fetch 2 Aspiration Catheter, which is used for small vessels when a manual thrombectomy device is preferred to resolve small, fresh thrombi in the peripheral and coronary arteries. The deal also includes the JetStream Atherectomy System, a versatile debulking solution for breaking apart and removing multiple lesion morphologies—from thrombus to challenging calcium deposits—from upper and lower extremity peripheral arteries.

“We expect this acquisition will help fuel continued growth for the company and we are looking forward to welcoming the team from Bayer Interventional to Boston Scientific,” said Mike Mahoney, President and CEO of Boston Scientific. “These technologies help physicians save both limbs and lives, and we believe this transaction will enable us to reach more effectively the greater than 27 million patients worldwide who suffer from the debilitating effects of peripheral vascular disease.”

“With this sale, our medical care division can concentrate on innovation and growth in radiology and diabetes care, where we already have a strong presence,” said Olivier Brandicourt, MD, CEO of Bayer HealthCare.

“The addition of Bayer Interventional will expand our commercial footprint and enhance our ability to provide physicians and healthcare systems with a complete portfolio of solutions to treat challenging vascular conditions,” added Jeff Mirviss, president of peripheral interventions at Boston Scientific. “We believe this acquisition will accelerate the growth of our Peripheral Interventions business and strengthen our position as a global leader in peripheral therapies.”

Related Links:

Boston Scientific
Bayer



Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical Examination & Procedure Light
Vega 80
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Critical Care

view channel
Image: Tubes attached to this artificial lung are connected to the patient\'s neck or chest, allowing blood to circulate and get oxygen while the patient is conscious. (Image Credit: Carnegie MellonImage: Tubes attached to this artificial lung are connected to the patient\'s neck or chest, allowing blood to circulate and get oxygen while the patient is conscious. (Image Credit: Carnegie Mellon University)University)

Portable Artificial Lung Technology Could Reshape Care for Chronic Lung Disease

Chronic lung disease can leave patients dependent on prolonged mechanical ventilation or awaiting transplantation, both of which carry substantial morbidity and healthcare costs. Ventilatory support may... Read more

Surgical Techniques

view channel
Image Credit: 123RF

Needle-Free Intrauterine Anesthesia Technique Reduces Pain During IUD Insertion

Pain during intrauterine device (IUD) placement often deters women from choosing this long-acting contraception. Avoiding or undertreating procedural pain can reduce uptake and satisfaction with effective... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.